Open Access Articles- Top Results for Entacapone



Entacapone (INN) (/ˌɛntəkəˈpn/ or /ɛnˈtækəpn/) is a drug that functions as a catechol-O-methyl transferase (COMT) inhibitor. It is used in the treatment of Parkinson's disease.

When administered in conjunction with dopaminergic agents such as L-DOPA, entacapone prevents COMT from metabolizing L-DOPA into 3-methoxy-4-hydroxy-L-phenylalanine (3-OMD) in the periphery, which does not easily cross the blood–brain barrier (BBB). Pharmacologically, entacapone is somewhat similar to carbidopa or benserazide, in that it is an inhibitor of an enzyme that converts L-DOPA into a compound that cannot cross the blood–brain barrier. Carbidopa and benserazide inhibit aromatic L-amino acid decarboxylase, which converts L-DOPA into dopamine, which cannot cross the blood–brain barrier.

Entacapone is a member of the class of drugs known as nitrocatechols.

Side effects

The most frequent undesirable effects caused by entacapone relate to the increased effects of L-DOPA, such as involuntary movements (dyskinesias). These occur most frequently at the beginning of entacapone treatment. Others common side effects are gastrointestinal problems, including nausea and abdominal pains. Diarrhea is a frequently reported and troublesome side effect that can result in unnecessary investigation, but resolves quickly on withdrawal of the drug.[1] Entacapone may cause urine to turn reddish-brown. This is a harmless side effect and is not a cause for concern. In studies with entacapone, some people have reported experiencing a dry mouth.


Entacapone is developed by Orion Pharma and marketed by Novartis under the trade name COMTan in the United States.

Stalevo is another medication developed by Orion Pharma and marketed by Novartis that contains entacapone in combination with carbidopa and levodopa (active ingredients in Sinemet).


  1. ^ Singer C (2002). "Adverse effects in the treatment of Parkinson’s disease". Expert Review of Neurotherapeutics 2 (1): 105–118. doi:10.1586/14737175.2.1.105. 

External links

Systematic (IUPAC) name
Clinical data
Trade names Comtan (single ingredient), Stalevo (multi-ingredient)
AHFS/ monograph
MedlinePlus a601236
Licence data US Daily Med:link
  • AU: B3
  • US: C (Risk not ruled out)
Pharmacokinetic data
Bioavailability 35%
Protein binding 98% (binds to serum albumin)
Metabolism Hepatic
Half-life 0.4-0.7 hour
Excretion Faeces (90%), Urine (10%)
130929-57-6 7pxY
PubChem CID 5281081
DrugBank DB00494 7pxY
ChemSpider 4444537 7pxY
UNII 4975G9NM6T 7pxY
KEGG D00781 7pxY
ChEBI CHEBI:4798 7pxY
Synonyms </td></tr>
Chemical data
Formula C14H15N3O5</td></tr>
305.286 g/mol</td></tr>
 14pxY (what is this?)  (verify)